Iterum Therapeutics (NASDAQ:ITRM) Rating Reiterated by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRMGet Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 300.00% from the company’s current price.

Iterum Therapeutics Trading Up 16.3 %

Shares of ITRM stock opened at $1.50 on Friday. The company has a market cap of $24.84 million, a P/E ratio of -0.57 and a beta of 2.33. The stock has a 50 day simple moving average of $1.53 and a two-hundred day simple moving average of $1.63. The company has a debt-to-equity ratio of 3.63, a quick ratio of 1.07 and a current ratio of 1.07. Iterum Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.50.

Iterum Therapeutics (NASDAQ:ITRMGet Free Report) last issued its earnings results on Thursday, March 28th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.08. Research analysts forecast that Iterum Therapeutics will post -1.76 earnings per share for the current year.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Articles

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.